Fri, Aug 29, 2014, 5:25 AM EDT - U.S. Markets open in 4 hrs 5 mins


% | $
Quotes you view appear here for quick access.

CytRx Corporation Message Board

  • anakiin anakiin Dec 18, 2013 9:58 AM Flag

    Mr. Feuerstein’s article WAS ALL WRONG

    there was another inaccuracy in Mr. Feuerstein’s article. The article claimed that 60 percent of the patients enrolled in the aldoxorubicin study came from India, Romania, Russia, and the Ukraine. Again, that is incorrect. Here is the distribution of all the patients in the trial:

    USA: 30 percent
    Hungary: 20 percent
    Australia: 12 percent
    Russia: 12 percent
    India: 11 percent
    Ukraine: 8 percent
    Romania: 7 percent

    This distribution indicates that only 38 percent of those enrolled in the trial are from India, Romania, Russia, and the Ukraine. The other 62 percent are from the USA, Hungary, and Australia (extremely reliable geographies for reporting credible and reproducible clinical trial data since Mr. Feuerstein considers the other countries to be less trustworthy). Mr. Feuerstein also failed to mention that the Ziopharm trial, which he holds in high regard, also had clinical sites in Russia, India, and Romania as well as sites in Guatemala, Panama, Columbia and Chile. Mr. Feuerstein was bullish on Ziopharm before its trial failed.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.37+0.03(+0.90%)Aug 28 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Viacom, Inc.
NasdaqGSThu, Aug 28, 2014 4:00 PM EDT
Williams-Sonoma Inc.
NYSEThu, Aug 28, 2014 4:02 PM EDT